Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise

Expert Opinion on Drug Safety

Volumn 15, Issue 10, 2016, Pages 1421-1426

  Hermanson, Terhi ^a   Bennett, Charles L ^a,b,c   Macdougall, Iain C ^d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adverse drug reactions; anaphylactic; anemia; chronic kidney disease; darbepoetin; epoetin; erythropoiesis stimulating agent; hemodialysis; hemoglobin; peginesatide; pharmacovigilance

Indexed keywords

PEGINESATIDE; ANTIANEMIC AGENT; PEPTIDE; RECOMBINANT PROTEIN;

ANAPHYLAXIS; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG RECALL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPLICATION; HEMODIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

ANEMIA; DRUG APPROVAL; HEMATINICS; HUMANS; PEPTIDES; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84983273833     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1218467     Document Type: Article

References (23)

1. I.C.Macdougall Erythropoiesis-stimulating agents in chronic kidney disease. In:N.Turner, D.J.Goldsmith, C.G.Winearls, et al. editors. Oxford textbook of clinical nephrology. Oxford:Oxford University Press; 2015.
2. S.C.Palmer, V.Saglimbene, J.C.Craig, et al. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014 Mar 31;3:CD009297.
3. M.P.Curran, P.L.McCormack. Methoxy polyethylene glycol-epoetin beta:a review of its use in the management of anaemia associated with chronic kidney disease. Drugs. 2008;68:1139–1156.
4. N.C.Wrighton, F.X.Farrell, R.Chang, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996 Jul 26;273(5274):458–464.
5. I.C.Macdougall, J.Rossert, N.Casadevall, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361(19):1848–1855.•• A pivotal study.
6. Q.Fan, K.K.Leuther, C.P.Holmes, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006 Oct;34(10):1303–1311.
7. Highlights of prescribing information for Omontys. Food and Drug Administration; 2012 [cited 2016 Jan29]. Available from::http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s000lbl.pdf in
8. I.C.Macdougall, A.Wiecek, B.Tucker, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011;6:2579–2586.
9. S.Fishbane, B.Schiller, F.Locatelli, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307–319.•• A pivotal study.
10. I.C.Macdougall, R.Provenzano, A.Sharma, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013;368(4):320–332.•• A pivotal study.
11. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Withdrawal Assessment report for Omontys. EMA/419554/2013; [updated 2013 Apr 25; cited 2016 Jan25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2013/09/WC500148933.pdf• The detailed peginesatide analysis of the European Medicines Agency.
12. S.D.Solomon, H.Uno, E.F.Lewis, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–1155.
13. E.D.Weinhandl, D.T.Gilbertson, A.J.Collins, et al. Relative safety of peginesatide and epoetin alfa. Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1003–1011.
14. C.L.Bennett, S.Jacob, J.Hymes, et al. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014 May 22; 370(21):2055–2056.•• A pivotal study.
15. J.A.Berlin, S.C.Glasser, S.S.Ellenberg. Adverse event detection in drug development:recommendations and obligations beyond phase 3. Am J Public Health. 2008 Aug;98(8):1366–1371.
16. C.L.Bennett, S.Luminari, A.R.Nissenson, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–1408.
17. Health Sciences Authority of Singapore. Contraindication of subcutaneous administration of Eprex® (epoetin alfa) in Singapore in chronic kidney disease patients; [updated 2013 Dec 31; cited 2016 May9]. Available from: http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2013/contraindication_of.html
18. A.M.Lincoff, R.Mehran, T.J.Povsic, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI):a randomised clinical trial. Lancet. 2016;387(10016):349–356. doi:10.1016/S0140-6736(15)00515-2.
19. I.C.Macdougall, A.J.Bircher, K.U.Eckardt, et al. Iron management in chronic kidney disease:conclusions from a “Kidney Disease:Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2016 Jan;89(1):28–39.
20. I.C.Macdougall, N.Casadevall, F.Locatelli, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia:the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30(3):451–460.
21. D.Rampton, J.Folkersen, S.Fishbane, et al. Hypersensitivity reactions to intravenous iron:guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676.
22. J.L.Weaver, M.Boyne, E.Pang, et al. Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog. Toxicol Appl Pharmacol. 2015;287:246–252.
23. J.Kotarek, C.Stuart, S.H.De Paoli, et al. Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events. J Pharm Sci. 2016;105(3):1023–1027.